Biopharma Resilience. Up or down?

Understanding the resilience of the global biopharma industry has never been more important. We surveyed biopharma experts globally for the latest edition of Cytiva's Global Biopharma Resilience Index. It measures the strength of the global pharma and bio-pharma industry across five categories: supply chain resilience, talent pool, R&D ecosystems, manufacturing agility, and government policy and regulation.

In summary: where the industry has most leverage and control, things have improved. Where the complexities of collaboration across industry, academia, non-profits, translational centers and governments, our survey participants say the industry is struggling to make progress. This makes sense: the post-COVID reset is challenging organizations everywhere.

The index provides insight into the challenges faced by the industry, from capital costs, talent shortages, and regulatory difficulties, to disruption from global events. Read the expert opinions on building a more resilient biopharma industry, and what countries should be doing to work collaboratively and foster innovation.

The?#biopharma?industry's overall resilience has declined by eight percent since 2021. Join our discussion of this and other key findings of the 2023 Global Biopharma Resilience Index featuring?Emmanuel Abate, President of Genomic Medicine, Cytiva - live tomorrow from?#BIO2023! Register here:?https://cytiva.link/cg2ks